Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18290052 | 0.86 | MAPK1 (0.34) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL6525725 | 0.82 | CA14 (0.34) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL2713441 | 0.82 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL20326558 | 0.79 | CA1 (0.45) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL1760208 | 0.78 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL13490197 | 0.78 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL842922 | 0.78 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL25925036 | 0.77 | CA1 (0.35) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL1025291 | 0.77 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL12778070 | 0.77 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109906227-B | 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones | 上海瑛派药业有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-110003214-B | Substituted pyrazolo [1,5-a ] pyrimidine compounds as TRK kinase inhibitors | 阵列生物制药公司 | 2021-12-21 | — | — | CN | disclosed |
| US-20200354404-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-11-12 | — | — | US | disclosed |
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Array BioPharm Inc. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-02-21 | — | — | US | disclosed |
| US-20180263984-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-09-20 | — | — | US | disclosed |
| US-10077243-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2018-09-18 | — | — | US | disclosed |
| EP-3299372-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OFSUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2451812-B1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20090240055-A1 | Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof | KREPSKI LARRY R | 2009-09-24 | — | — | US | disclosed |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | ASUBIO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1937683-A1 | METHOD FOR 1H-IMIDAZOÝ4,5-c¨PYRIDINES AND ANALOGS THEREOF | Coley Pharmaceutical Group, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007035935-A1 | METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | HDAC6 331/4885HDAC1 293/4885HDAC2 282/4885 |
| US-20090240055-A1 | Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof | CYP4B1, CYP4F8, CYP4X1 | HDAC6 1670/4885HDAC1 672/4885HDAC2 1079/4885 |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | HDAC6 666/4885HDAC1 1978/4885HDAC2 1697/4885 |
| US-10251889-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | TXK, FRK, LTK | HDAC6 2791/4885HDAC1 1245/4885HDAC2 1667/4885 |
| US-10077243-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | GRM5, GRIK5, GRM2 | HDAC6 451/4885HDAC1 1158/4885HDAC2 1478/4885 |
| US-20090131413-A1 | Thienopyrazole Derivative Having PDE7 Inhibitory Activity | PDE7A, PDE7B, PDE3B | HDAC6 1276/4885HDAC1 443/4885HDAC2 384/4885 |
| US-20200354404-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | DNPEP, PEPD, ANPEP | HDAC6 3399/4885HDAC1 4630/4885HDAC2 4764/4885 |
| US-20180263984-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | HDAC6 2791/4885HDAC1 1245/4885HDAC2 1667/4885 |
| US-10758542-B2 | Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors | LTK, TXK, FRK | HDAC6 2922/4885HDAC1 1498/4885HDAC2 1846/4885 |
| US-20190055204-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | HDAC6 360/4885HDAC1 877/4885HDAC2 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.